IgE‐mediated anaphylaxis and allergic reactions to idursulfase in patients withHunter syndrome

Abstract

Anaphylaxis related to infusion of idursulfase is mediated by anti-idursulfase IgE antibody, which might be produced by de novo synthesis. SPT is useful in predicting the occurrence of anti-idursulfase IgE-mediated anaphylaxis during infusion.

An overview of Korean patients with mucopolysaccharidosis and collaboration through the Asia Pacific MPS Network

“…However, life-threatening anaphylactic reactions can occur in patients receiving ERT. In a previous study (29), anaphylaxis associated with the infusion of idursulfase was mediated by anti-idursulfase IgE antibodies, which can be produced by de novo synthesis. The skin-prick test was useful at predicting the occurrence of antiidursulfase IgE-mediated anaphylaxis during infusion.…”

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction

“…For some patients, however, immune responses to ERT have resulted in adverse reactions, including mild to life-threatening hypersensitivity responses [10,11,12].…”

“…A C C E P T E D M A N U S C R I P T with IgE mAb) [35]. Although infusion reactions can be challenging to manage in some patients, they…”

Profile of idursulfase for the treatment of Hunter syndrome

“…21 No IgE antibodies were detected in any of the studies described above. 14,[19][20][21] Recently, Kim et al 38 identified specific …”

“…The authors concluded that this immediate-type hypersensitivity is mediated by antiidursulfase IgE antibodies, which might be produced by the de novo synthesis. 38 The results of a post hoc analysis of data from the Phase II/III study and extension study were presented by Barbier et al, 39 in order to evaluate the association between anti-idursulfase antibody status and the efficacy and safety of idursulfase, administered at the dose of 0.5 mg/kg weekly for 105 weeks, in an attenuated, treatment-naïve population of patients aged 5 years and older. Thirty-two out of the 63 patients analyzed (51%) developed at least a single sample that was positive for anti-idursulfase antibodies without a decrease in 6MWT distance, a decrease in %FVC response, or an increase in liver and/or spleen volume.…”